Azenta, Inc.

Exclusive licensing agreement with Elegen and acquisition of SynPlexity strengthen gene synthesis capabilities, expand high-throughput discovery workflows, and position GENEWIZ for long-term growth BURLINGTON, Mass., Oct. 30, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced strategic investments to advance the next phase of growth for its GENEWIZ business.

BURLINGTON, Mass., Oct. 28, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2026 earnings which ended on September 30, 2026, on Tuesday, November 10, 2026, after the market closes.

Azenta, Inc. (NASDAQ: AZTA - Get Free Report)'s share price fell 9.3% on Friday. The company traded as low as $33.20 and last traded at $33.1190. Approximately 462,967 shares were traded during mid-day trading, a decline of 51% from the average daily volume of 940,976 shares. The stock had previously closed at $36.52. Analyst Ratings Changes

Azenta, Inc. (NASDAQ: AZTA - Get Free Report) has been given an average recommendation of "Hold" by the seven analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The